CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
of the Chinese Antibody Society
Register today to reserve your seat
CAS Members can sign in to view recordings
Emerging targets for immuno-oncology
The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond
In our two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development.
New Horizon of Antibody Drug Conjugate (ADC)
FREE Registration is now open for mAbTalks series in 2021 - “New Horizon of Antibody-Drug Conjugate (ADC)” virtual symposium. The symposium will be held online on May 23, 2021. In this half-day event, speakers from both industry and academia will share their insights in diverse topics of ADC-based therapeutics, including discovery & new techniques, clinical development.
Revisit the Perspectives of Bispecific Antibodies under the COVID-19 Pandemic
Bispecific and multispecific antibody-based therapies are at the cutting-edge of therapeutic biologics development, and provide new opportunities to address unmet medical needs. In our one-day symposium, eight speakers from both industry and academia will share insights on all aspects of bispecific antibody-based therapeutic development, including novel targets and molecular formats, development of the lead candidate from discovery to clinics, CMC challenges and strategies, regulatory considerations, patent protection strategies, and COVID-19 related therapeutics.